Sudden Death in Children Receiving Norpramin®: A Review of Three Reported Cases and Commentary

MARK A. RIDDLE, J. CRAIG NELSON, CHARLES S. KLEINMAN, ANN RASMUSSON, JAMES F. LECKMAN, ROBERT A. KING, DONALD J. COHEN

Research output: Contribution to journalArticlepeer-review

124 Scopus citations

Abstract

The 1990 “package insert” for Norpramin®, the Merrell Dow Pharmaceuticals Inc., brand of desipramine, was changed to include the following statement in the Adverse Reactions section, “There has been a report of an ‘acute collapse’ and ‘sudden death’ in an eight-year-old (18 kg) male, treated for two years for hyperactivity. There have been additional reports of sudden death in children.” The purpose of this commentary is to review what is known about the three reported cases of sudden death and to discuss the implications of these tragedies for children receiving treatment with tricyclic drugs. J. Am. Acad. Child Adolesc. Psychiatry, 1991, 30, 1:104–108.

Original languageEnglish (US)
Pages (from-to)104-108
Number of pages5
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume30
Issue number1
DOIs
StatePublished - 1991
Externally publishedYes

Keywords

  • children
  • desipramine
  • sudden death

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Sudden Death in Children Receiving Norpramin®: A Review of Three Reported Cases and Commentary'. Together they form a unique fingerprint.

Cite this